File(s) not publicly available
Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study
journal contribution
posted on 2023-06-08, 11:17 authored by Valerie JenkinsValerie Jenkins, David J Bloomfield, Valerie ShillingValerie Shilling, Trudi L EdgintonOBJECTIVE: To examine, in a prospective study, the influence that temporary reversible medical castration for localized prostate cancer has on cognition, by assessing whether temporary 3-5 month treatment with a luteinizing-hormone releasing hormone (LHRH) agonist before radical radiotherapy had a short- or long-term affect on cognitive function. PATIENTS, SUBJECTS AND METHODS: Thirty-two patients with localized prostate cancer had cognitive assessments at baseline (T1) before the start of drug treatment, at 3 months (T2) or on completing drug treatment but before radiotherapy, and 9 months later (T3). Eighteen men with no prostate cancer (controls subjects) completed the cognitive tests at the same times. In addition, psychological functioning and quality of life were assessed at the same times, together with serum free and bound testosterone, beta-oestradiol and sex hormone-binding globulin levels. RESULTS: There was a significant cognitive decline (on at least one cognitive task) at T2 in 15 (47%) patients vs three (17%) of controls (odds ratio 4.412, P = 0.033). Most patients (nine of 15) who had a change in performance declined on tasks of spatial memory and ability. At T3 there was significant cognitive decline in 11 (34%) patients and five (28%) control subjects (odds ratio 1.37, P = 0.631). CONCLUSION: This pilot study suggests that short-term LHRH therapy for early-stage prostate cancer has modest short-term consequences on men's cognitive functioning; a larger prospective study is warranted.
History
Publication status
- Published
Journal
BJU InternationalISSN
1464-4096Publisher
WileyExternal DOI
Issue
1Volume
96Page range
48-53Department affiliated with
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications
Notes
1464-4096 (Print) Clinical Trial Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov'tFull text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2012-04-17Usage metrics
Categories
No categories selectedKeywords
AgedAndrogen Antagonists/*adverse effectsAntineoplastic AgentsHormonal/*adverse effectsCognition Disorders/*chemically inducedCyproterone Acetate/*adverse effectsGoserelin/*adverse effectsHumansIntelligenceMaleMemory Disorders/chemically inducedMiddle AgedNeoadjuvant Therapy/*adverse effectsPilot ProjectsProstatic Neoplasms/*drug therapy/psychologyQuality of LifeQuestionnairesSpeech Disorders/chemically induced
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC